| Literature identifier | Study type | Test dosage | Effective dosage | Endocrine-mediated endpoints | Systems-level perturbations |
|---|---|---|---|---|---|
| PMID:1601208 | IVR | 100 mg/kg/day | 100 mg/kg/day | Decreased thymus gland weights | Immunological endocrine-mediated perturbations |
| IVR | 300 mg/kg/day | 300 mg/kg/day | Decreased thymus gland weights | Immunological endocrine-mediated perturbations | |
| IVR | 300 mg/kg/day | 300 mg/kg/day | Alterations in immune responses | Immunological endocrine-mediated perturbations | |
| IVR | 150 mg/kg/day | 150 mg/kg/day | Increased spleen weights | Immunological endocrine-mediated perturbations | |
| IVR | 150 mg/kg/day | 150 mg/kg/day | Alterations in immune responses | Immunological endocrine-mediated perturbations | |
| IVR | 225 mg/kg/day | 225 mg/kg/day | Alterations in immune responses | Immunological endocrine-mediated perturbations | |
| IVR | 225 mg/kg/day | 225 mg/kg/day | Decreased thymus gland weights | Immunological endocrine-mediated perturbations | |
| IVR | 225 mg/kg/day | 225 mg/kg/day | Increased spleen weights | Immunological endocrine-mediated perturbations | |
| IVR | 50 mg/kg/day | - | No significant effects observed | - | |
| IVR | 200 mg/kg/day | 200 mg/kg/day | Alterations in immune responses | Immunological endocrine-mediated perturbations | |
| PMID:16321413 | IVR | 250 mg/kg | 250 mg/kg | Affects cytokine signaling | Immunological endocrine-mediated perturbations |
| IVR | 250 mg/kg | 250 mg/kg | Alterations in immune responses | Immunological endocrine-mediated perturbations | |
| PMID:7935259 | IVR | 50 - 300 mg/kg | 50 - 300 mg/kg | Decreased prolactin levels | Reproductive endocrine-mediated perturbations |
| IVR | 50 - 300 mg/kg | 50 - 300 mg/kg | Decreased LH levels | Reproductive endocrine-mediated perturbations | |
| IVR | 50 - 300 mg/kg | 50 - 300 mg/kg | Affects ovulation | Reproductive endocrine-mediated perturbations | |
| IVR | 25 - 100 mg/kg | 25 - 100 mg/kg | Decreased prolactin levels | Reproductive endocrine-mediated perturbations | |
| IVR | 25 - 100 mg/kg | 25 - 100 mg/kg | Decreased LH levels | Reproductive endocrine-mediated perturbations | |
| IVR | 25 - 100 mg/kg | 25 - 100 mg/kg | Decreased noradrenaline levels | Neurological endocrine-mediated perturbations |
We have built a comprehensive resource which compiles potential endocrine disrupting chemicals (EDCs) based on the observed adverse effects or endocrine-mediated endpoints in published experiments on humans or rodents to support basic research. We are not responsible for any errors or omissions in the published research articles or supporting literature on potential EDCs compiled in this resource. Users are advised to exercise their own judgement on the weight of evidence for potential EDCs compiled in this resource. Importantly, our sole goal to build this resource on potential EDCs is to enable future basic research towards better understanding of the systems-level perturbations upon chemical exposure rather than influencing regulatory advice on chemical use.